Screener
BridgeBio Pharma BBIO Contract Liabilities
Contract Liabilities at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| 2027 Notes, net | — | 547,015 |
| Deferred royalty obligations, net (3) | 871,185 | 855,030 |
| Operating lease liabilities, net of current portion | 14,216 | 3,811 |
| Deferred revenue, net of current portion | 11,776 | 13,080 |
| Other long-term liabilities | 229 | 244 |
| Total liabilities | 3,639,856 | 3,012,606 |
| Commitments and contingencies (Note 7) | ||
| Redeemable convertible noncontrolling interests | (951) | (570) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's contract liabilities?
- BridgeBio Pharma (BBIO) reported contract liabilities of $11.78M in Q1 2026.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.
Ask your AI about BridgeBio Pharma's contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude